Even for children with persistent asthma, the most recent evidence suggests that adding long-acting beta2 agonists (LABA) to inhaled corticosteroids
(ICS) does not result in a statistically significant reduction in exacerbations. However, there is some evidence that LABA/ICS combination therapy
increases the risk of hospital admissions and severe asthma-associated adverse events, particularly among asthmatic children aged 4 to 11 years old.
Due to the limited paediatric evidence on the safety and efficacy of longacting beta2 agonists, the use of ICS alone is therefore recommended for
the initial preventative therapy and the only therapy for children with mild to moderate asthma.
- Canadian Agency for Drugs and Technologies in Health (CADTH). Long-Acting Beta2-Agonist and Inhaled Corticosteroid Combination Therapy for Adult Persistent Asthma: Systematic Review of Clinical Outcomes and Economic Evaluation. CADTH Technology Overviews. 2010;1(3):e0120.
- Chauhan BF, Chartrand C, Ni Chroinin M, et al. Addition of long-acting beta2-agonists to inhaled corticosteroids for chronicasthma in children. Cochrane Database Syst Rev. 2015 24;(11):CD007949.
- McMahon AW, Levenson MS, McEvoy BW, et al. Age and Risks of FDA-Approved Long-Acting 2-Adrenergic Receptor Agonists. Pediatrics. 2011;128(5):e1147-54.
- van Asperen PP, Mellis CM, Sly PD, Robertson C. The role of corticosteroids in the management of childhood asthma. The Thoracic Society of Australia and New Zealand, 2010.